CLINICAL TRIALS PROFILE FOR BRICANYL

All Clinical Trials for Bricanyl

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00220259 ↗	Cystic Fibrosis Withdrawal of Inhaled Steroids Evaluation Study (CF WISE Study)	Completed	Cystic Fibrosis Trust	N/A	2001-05-01	The overall aim of this study is to find out whether taking regular inhaled steroids (eg Pulmicort, Flixotide, Becotide, Becloforte) is good for the lungs of children and adults with cystic fibrosis (CF). Some patients are put on inhaled steroids because they are wheezy despite taking regular bronchodilators (inhaled medicines that help open up the airways eg Ventolin, Bricanyl). Occasionally young children are put on them when they wheeze with colds, and have simply remained on them ever since. However many CF patients have been put onto inhaled steroids because their doctors thought it might reduce the inflammation in the lungs and help improve lung function. This inflammation (which is swelling of the lining of the airways) is known to be important in CF and results from recurrent chest infections. Although it is believed, in theory, that inhaled steroids should be useful for most CF patients, we are not sure how well they work in CF and it has not yet been possible to prove this with standard studies. This would normally involve starting inhaled steroids in patients who have not been taking them. We have therefore taken a different approach, namely to withdraw them from some patients who have been on them for a long time, to see if there is any effect of stopping them. It is important that we answer this question, as we do not want CF patients taking medicines that may be unnecessary. CF patients already have to take many oral and inhaled medicines and if we can cut down this burden, it would be helpful for everyone. Of course, we may find that patients do need these medicines but at least we will then be certain that it is for a good reason. The main hypothesis is that withdrawing inhaled steroids is not associated with an earlier onset of acute chest exacerbations.
NCT00220259 ↗	Cystic Fibrosis Withdrawal of Inhaled Steroids Evaluation Study (CF WISE Study)	Completed	GlaxoSmithKline	N/A	2001-05-01	The overall aim of this study is to find out whether taking regular inhaled steroids (eg Pulmicort, Flixotide, Becotide, Becloforte) is good for the lungs of children and adults with cystic fibrosis (CF). Some patients are put on inhaled steroids because they are wheezy despite taking regular bronchodilators (inhaled medicines that help open up the airways eg Ventolin, Bricanyl). Occasionally young children are put on them when they wheeze with colds, and have simply remained on them ever since. However many CF patients have been put onto inhaled steroids because their doctors thought it might reduce the inflammation in the lungs and help improve lung function. This inflammation (which is swelling of the lining of the airways) is known to be important in CF and results from recurrent chest infections. Although it is believed, in theory, that inhaled steroids should be useful for most CF patients, we are not sure how well they work in CF and it has not yet been possible to prove this with standard studies. This would normally involve starting inhaled steroids in patients who have not been taking them. We have therefore taken a different approach, namely to withdraw them from some patients who have been on them for a long time, to see if there is any effect of stopping them. It is important that we answer this question, as we do not want CF patients taking medicines that may be unnecessary. CF patients already have to take many oral and inhaled medicines and if we can cut down this burden, it would be helpful for everyone. Of course, we may find that patients do need these medicines but at least we will then be certain that it is for a good reason. The main hypothesis is that withdrawing inhaled steroids is not associated with an earlier onset of acute chest exacerbations.
NCT00220259 ↗	Cystic Fibrosis Withdrawal of Inhaled Steroids Evaluation Study (CF WISE Study)	Completed	Royal Brompton & Harefield NHS Foundation Trust	N/A	2001-05-01	The overall aim of this study is to find out whether taking regular inhaled steroids (eg Pulmicort, Flixotide, Becotide, Becloforte) is good for the lungs of children and adults with cystic fibrosis (CF). Some patients are put on inhaled steroids because they are wheezy despite taking regular bronchodilators (inhaled medicines that help open up the airways eg Ventolin, Bricanyl). Occasionally young children are put on them when they wheeze with colds, and have simply remained on them ever since. However many CF patients have been put onto inhaled steroids because their doctors thought it might reduce the inflammation in the lungs and help improve lung function. This inflammation (which is swelling of the lining of the airways) is known to be important in CF and results from recurrent chest infections. Although it is believed, in theory, that inhaled steroids should be useful for most CF patients, we are not sure how well they work in CF and it has not yet been possible to prove this with standard studies. This would normally involve starting inhaled steroids in patients who have not been taking them. We have therefore taken a different approach, namely to withdraw them from some patients who have been on them for a long time, to see if there is any effect of stopping them. It is important that we answer this question, as we do not want CF patients taking medicines that may be unnecessary. CF patients already have to take many oral and inhaled medicines and if we can cut down this burden, it would be helpful for everyone. Of course, we may find that patients do need these medicines but at least we will then be certain that it is for a good reason. The main hypothesis is that withdrawing inhaled steroids is not associated with an earlier onset of acute chest exacerbations.
NCT00259766 ↗	SHARE - Symbicort and Health Economics in a Real Life Evaluation	Completed	AstraZeneca	Phase 3	2004-04-01	The purpose of this study is to compare health-related costs and asthma control in ordinary clinical practice during 12 months for Symbicort® given as a low maintenance dose plus as needed compared to a free combination of Pulmicortâ and Oxis® plus Bricanyl® as needed, and Symbicort fixed dosing plus Bricanyl as needed in asthmatic patients not adequately controlled on inhaled glucocorticosteroids alone.
NCT00326053 ↗	Prevention of Asthma Relapse After Discharge From Emergency	Completed	AstraZeneca	Phase 3	2006-05-01	The purpose of this study is to compare the Symbicort® Turbuhaler® to both Pulmicort® Turbuhaler® and Bricanyl® Turbuhaler® for the treatment of asthma after discharge from the emergency room
NCT00989833 ↗	Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients	Completed	AstraZeneca	Phase 2	2009-09-01	1. The primary objective of this study is: - To evaluate the magnitude of the protective effect of the combination of budesonide and formoterol on an as-needed basis compared to the use of terbutaline as-needed on exercise induced bronchoconstriction in adults and adolescents with mild intermittent asthma 2. The secondary objectives of this study are: - To evaluate the magnitude of the protective effect of the combination of budesonide and formoterol as-needed compared to regular once daily use of budesonide plus terbutaline as-needed on exercise induced bronchoconstriction in adults and adolescents with mild intermittent asthma - To evaluate safety of budesonide/formoterol as-needed, terbutaline as-needed and regular use of budesonide + terbutaline as-needed as terms of adverse event

Clinical Trial Conditions for Bricanyl

Condition Name

Condition Name for Bricanyl
Intervention	Trials
Asthma	4
Acute Asthma	1
Acute Exacerbation of Chronic Obstructive Airways Disease	1
Cystic Fibrosis	1

Condition MeSH

Condition MeSH for Bricanyl
Intervention	Trials
Asthma	6
Lung Diseases, Obstructive	1
Cystic Fibrosis	1
Lung Diseases	1

Clinical Trial Locations for Bricanyl

Trials by Country

Trials by Country for Bricanyl
Location	Trials
Canada	10
Sweden	3
Tunisia	3
United Kingdom	2
Norway	1

Trials by US State

Trials by US State for Bricanyl
Location	Trials
New York	1

Clinical Trial Progress for Bricanyl

Clinical Trial Phase

Clinical Trial Phase for Bricanyl
Clinical Trial Phase	Trials
Phase 3	4
Phase 2/Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for Bricanyl
Clinical Trial Phase	Trials
Completed	7
Terminated	1
Unknown status	1

Clinical Trial Sponsors for Bricanyl

Sponsor Name

Sponsor Name for Bricanyl
Sponsor	Trials
AstraZeneca	4
University of Monastir	2
Cystic Fibrosis Trust	1

Sponsor Type

Sponsor Type for Bricanyl
Sponsor	Trials
Other	6
Industry	6

Bricanyl Market Analysis and Financial Projection

Last updated: April 27, 2026

BRICANYL (terbutaline): What the clinical-trials landscape says and how to model market outlook

What is BRICANYL and what is its current clinical use?

BRICANYL is a brand of terbutaline, a short-acting beta-2 adrenergic agonist (SABA) used for reversible bronchospasm in conditions such as asthma and bronchospasm associated with chronic lung disease. In most markets, terbutaline is used for acute symptom relief, not as disease-modifying therapy.

Clinical-trials implication: For mature SABA brands like BRICANYL, new pivotal trial activity is often limited unless a company is seeking label expansions, new formulations (dose forms, inhaler technology), or life-cycle changes (e.g., pediatric labeling, delivery device upgrades).

---

What does the current clinical-trials update show (sponsor-level and trial-activity level)?

Sufficient information is not available in the provided prompt to produce a complete and accurate clinical-trials update for BRICANYL, including: trial phase distribution, ongoing studies, recruitment status, endpoints, sponsor pipeline, geographic coverage, or any publication-to-regulatory crosswalk.

Under strict constraints, the response below contains only market-model framing based on the drug class and brand maturity, without presenting specific trial counts or dates that cannot be verified from the prompt.

---

How does BRICANYL typically compete in the respiratory market?

BRICANYL competes in a treatment space dominated by rapid-reliever therapy and by availability, formulary status, and device/dose convenience.

Competitive set (practical):

• Other SABAs: albuterol (salbutamol), levalbuterol
• Other bronchodilator classes: anticholinergics (e.g., ipratropium), LABA-based maintenance regimens (as context)
• Maintenance controllers that change reliever usage patterns: inhaled corticosteroids (ICS), ICS/LABA, LAMA depending on guideline

Why this matters for forecasting: SABA brand performance tends to track:

• Generic penetration
• Formulary preference
• Supply and pricing dynamics
• Guideline-driven SABA exposure trends (patients on controllers use relievers less often)

---

What market drivers apply to a SABA brand like BRICANYL?

Demand drivers

• Acute symptom treatment frequency (higher during seasonal peaks, viral seasons, exacerbation-prone populations)
• Access and reimbursement for reliever therapy
• Pediatric and emergency-use patterns where relevant

Demand headwinds

• Shift to controller-based regimens reducing reliever-only reliance
• Broad generic availability for terbutaline and competing SABAs in many geographies
• Safety and guideline emphasis that can reduce overuse

Commercial reality for mature SABAs

• Brand value typically concentrates in existing market share, device convenience, and pricing/rebate execution, not in step-change clinical differentiation.

---

How should you project BRICANYL revenue and volume without assuming new clinical catalysts?

A workable projection model for BRICANYL should separate (1) base demand, (2) share capture/loss, and (3) price erosion.

1) Base demand (volume) Use a composite of:

• Total reliever market growth is usually modest
• Weather/seasonality and exacerbation rates drive short-term swings
• Controller adoption can reduce reliever intensity

2) Share dynamics (brand vs. class) Model share with:

• Generic displacement risk (if not already fully reflected in current market conditions)
• Formulary tier changes
• Tender and hospital contracting patterns (if relevant to the product)

3) Pricing (net sales) Net sales for mature respiratory brands generally:

• Decline or stagnate as generics expand
• Improve only if a product is protected by formulation/device uniqueness or local market barriers

Projection approach (signal-based)

• If no label expansion or differentiated formulation is underway, set a low single-digit volume growth or decline and a negative price trend.
• If device upgrades exist, incorporate partial offset through conversion to a preferred delivery form.
• If regulatory or safety labeling materially tightens use, add demand drag.

Because the prompt provides no verifiable trial/regulatory timeline, this analysis does not claim new clinical catalysts.

---

What scenarios are reasonable for BRICANYL (without new pivotal trial assumptions)?

Build three revenue scenarios from volume and net price.

Scenario	Volume trajectory (YoY)	Net price trend (YoY)	Revenue implication
Bear	-2% to -5%	-2% to -6%	Mid-to-high single-digit decline
Base	-1% to +2%	-1% to -4%	Flat-to-low single-digit decline
Bull	+2% to +4%	-1% to +1%	Low-to-mid single-digit growth

Operational triggers to map into scenarios (checkpoints):

• Generic penetration pace in primary markets
• Formulary outcomes (hospital and payer)
• Any supply disruptions or contraction of competitors
• Changes in guideline emphasis on SABA use and controller intensity

---

Where does BRICANYL likely sit in the lifecycle risk map?

For a SABA brand with long-standing clinical use:

• Regulatory and clinical novelty risk is low unless tied to new formulation/delivery or label expansions.
• Commercial risk is primarily competitive and pricing-driven.
• Manufacturing and distribution reliability can be a larger driver of share stability than clinical evidence.

---

What investment or R&D decisions would follow from this profile?

If you are assessing BRICANYL for investment:

• Treat BRICANYL as a value-and-share management asset, not a pipeline growth vehicle.
• Rely more on contracting, pricing, and supply than on expecting clinical-trial-driven step changes.

If you are assessing adjacent development:

• Terbutaline-family development typically wins when it improves device usability, dosing reliability, or formulation tolerability.
• Clinical-trial effort is justified when it supports meaningful usability or regulatory differentiation, not when it repeats known SABA efficacy.

---

Key Takeaways

• BRICANYL (terbutaline) is a mature SABA used for reversible bronchospasm; the brand value typically depends on formulary access and pricing more than new clinical differentiation.
• The prompt does not provide enough information to produce a complete, verified clinical-trials update (trial-level counts, phase, recruiting status, sponsors, endpoints, and timelines).
• For market projection, model BRICANYL using volume (seasonality and reliever demand) plus net price erosion (generic and competitive pressure).
• A practical forecast range for mature SABA brands is flat-to-declining revenue under base assumptions, with bear and bull cases driven by share retention and pricing outcomes rather than clinical catalysts.

FAQs

1. Is BRICANYL considered a controller or a reliever?
   BRICANYL is a reliever (SABA) used for acute bronchospasm symptom relief, not a maintenance controller.

2. What most affects BRICANYL revenue in mature markets?
   Generic competition, formulary placement, and net price trends usually dominate over new clinical trial drivers.

3. Do controller guidelines reduce SABA market growth?
   Yes, the trend toward controller-based regimens often reduces reliever frequency per patient, which can constrain market growth.

4. What type of R&D would be most credible for a terbutaline brand?
   Work that improves delivery device performance, formulation usability, or specific label segments is more likely to support commercial differentiation.

5. How should projections be structured for BRICANYL?
   Use a three-part model: base reliever demand (volume), brand share dynamics, and net pricing (including rebate and tender effects), then run bear/base/bull ranges.

---

References (APA)

[1] FDA. (n.d.). BRICANYL (terbutaline) prescribing information. U.S. Food and Drug Administration.
[2] European Medicines Agency. (n.d.). Product information for terbutaline-containing medicines. EMA.
[3] Global Initiative for Asthma (GINA). (2024). Global Strategy for Asthma Management and Prevention. GINA.
[4] Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2024). Global Strategy for Prevention, Diagnosis and Treatment of COPD. GOLD.